Albuminuria predicts cardiovascular disease (CVD) events but it is likely to vary over time in a nonlinear fashion. The aim of this study was to estimate the potentially differing predictive effect of albuminuria on the risk of CVD or related death over time. Data were from a cohort study of 3505 predominately indigenous adults from remote communities in Queensland, Australia, 1999-2006. Cox Proportional Hazards model analysis of the predictive effects of urinary albumin creatinine ratio on the risk of CVD or CVD-related death was undertaken for incident and prevalent CVD. Analyses sequentially removed those who had a cardiovascular event or related death for the first year through to six years. The baseline prevalence of microalbuminuria was 21.2% and for macroalbuminuria 6.7%. The incidence of CVD was 92 in 13,812 person-years. Microalbuminuria predicted incident CVD with a Hazard Ratio (HR) of 3.0 (95% CI 1.83 -4.96) and for macroalbuminuria HR 10.8 (95% CI 6.58 -17.68) and for those with pre-existing CVD, HR 2.6 (95% CI 1.65 -3.97) and HR 9.7 (95% CI 6.38 -14.82) respectively. People with macroalbuminuria who survived the first three years had a crude HR of an incident cardiovascular event or death of 13.0 (95% CI 6.45 -26.39) to a peak of 32.3 (95% CI 8.55 -121.77) for those who survived the first five years. The hazard appeared to drop in the 6th year although this is based on small numbers. The first three years after finding macroalbuminuria provide a potential window opportunity to actively manage the risk of incident CVD before the risk elevates.
INTRODUCTION
Albuminuria is a well established independent risk factor for cardiovascular disease events and associated mortality. This has been reported in both high risk and general population cohorts [1] [2] [3] . The mechanism for this association is not clear, however a number of hypotheses have been proposed. The association may be accounted for by albuminuria as a marker of reduced renal function, which is associated with increased cardiovascular disease (CVD) risk [4] . Additionally, it may be that widespread endothelial damage leads both to albuminuria and CVD through enhanced atherogenesis [4] . It is also possible that a common factor, such as hypertension, leads to both albuminuria and CVD [5] .
The range of studies reporting this association assume constant risk (or hazard) over time. This is unlikely to be true biologically as a high level of macroalbuminuria is more likely in an advanced stage of disease such that the risk of a cardiovascular event is greater in the short term than those with lesser levels of macroalbuminuria, all other factors equal. As such, using a model such as the Cox model which assumes constant hazard over time may not adequately estimate the risk of albuminuria for cardiovascular disease. In this scenario, the hazard over the length of the study period may overestimate the risk in the short term and underestimate it in the long term. This has implications on the importance clinicians place on management of albuminuria in the prevention of both advanced renal and cardiovascular disease in the short term to reduce greater risk in the long term.
To examine this further, we used data from the Well Person's Health Check (WPHC), a cohort study in North Queensland conducted in 26 remote Aboriginal and Torres Strait Islander communities [6] . This general population cohort has previously documented high levels of albuminuria and CVD [7] and so provides an opportunity to examine the effect of changing risk of albuminuria on cardiovascular disease over time.
MATERIALS AND METHODS

Study Population
Baseline data were collected from 3505 people in 26 rural Indigenous communities in Far North Queensland, who participated in the "Well Person's Health Check" between 1999 and 2000 (methods for this cross-sectional study have been reported in detail elsewhere [6] ). Based on the local census data, the study achieved a participation rate of 44.5% with greater participation noted in smaller communities.
Albumin Creatinine Ratio
All participants were asked to provide urine from the first morning void or to delay providing the sample for at least two hours from the most recent void. First catch urine samples were self-collected in a sterile 50 ml container. All urine specimens were refrigerated at four to eight degrees centigrade immediately following collection. A five to ten millilitre sample from the collection jar was transferred into a ten-millilitre tube. Dipstick urinalysis (Combur-test, Roche) was performed on the remaining sample and the results for protein recorded. For the first 15 months of the recruitment period (of a total recruitment period of 34 months) albumin creatinine ratio (ACR) testing was performed when the participants' urine contained protein (detected on urinalysis) or they were known to have diabetes, hypertension or had a body mass index over 30 kg/m 2 . For the subsequent 19 months of recruitment ACR testing was performed routinely on all urine specimens [6] . Microalbuminuria was defined as a urinary ACR of 3.4 mg/mmol to 33.9 mg/mmol and macroalbuminuria of 34 mg/mmol or greater.
CVD Event or Related Death
A cardiovascular event or related death was determined from unit-level record linkage of the cohort members to hospitalisation records and deaths up to a census date of 1 January 2006. Hospitalisation and death records for consenting WPHC participants were identified by a manual search (conducted by a registered nurse with experience working in the region) of the Queensland Health hospital records systems. As there is no unique patient identifier in Queensland, a mapping table, which linked WPHC reference number, hospital facility code and local unit record number, was developed. This table was subsequently applied to the Queensland Hospital Admitted Patient Data Collection, and hospitalisation relevant to the match unit record, facility code tuples were extracted. Matching of death records was performed manually at the Queensland Registry of Births, Deaths and Marriages.
Hospitalisations were considered to be CVD related if they contained an International Classification of Diseases, ninth revision, clinical modification (ICD-9-CM) code commencing with 410, 411, 413 or 414, or an ICD-9-CM procedure code between 3600 and 3699, inclusive. For hospitalisations coded to the International Classification of Diseases, 10th revision, the diagnosis code range I20 -I25, and procedure code blocks 669 -679, inclusive, were used.
Both incident CVD and a separate analysis on the whole sample that also included those with pre-existing CVD were undertaken. Prior cardiovascular disease was determined from participant report of a history of cardiovascular disease or from a case note review at study entry or hospitalisation (using the same International Classification of Diseases codes as above) recorded prior to study entry.
Baseline Data
Current smoking was defined as regular smoking of at least one cigarette a day. Blood pressure was the average of three measurements taken while seated over a ten minute period. Height and weight were measured, with weight recorded to the nearest 0.1 kg and height recorded to the nearest centimetre. Body mass index was calculated as weight (kg) divided by the height squared (m 2 ) and categorised by using WHO definition of overweight and obesity [8] .
Blood for total cholesterol was collected by trained health staff. Blood was collected in an eight point millilitre clotted (SST) vacuum tube which was spun for 10 minutes in a portable centrifuge within one hour of collection and measured by photometric enzyme end point assay, using the Cobas Integra 700/400 (Roche Diagnostics, New York, USA).
Prior history of diabetes at baseline was determined from a report at interview of diabetes or case note review or a fasting blood glucose level of ≥7 mmol/L, 2-hour glucose tolerance test result of ≥11.1 mmol/L at study entry, or documented hospitalisation for diabetes prior to study entry (through the linkage process described above for ICD-09 codes E11-E14).
Study Sample
Those who did not have an ACR measured (n = 643) and missing data on variables blood pressure or smoking (a further n = 413), date of the first screen (n = 1) or for cause of death (n = 3) lead to a sample for analysis of 2445. Exclusion of those with pre-existing CVD brought the sample to 2349. As noted above, the majority of thethose participants who did and did not have an ACR taken or had missing data was undertaken, using chi square test or a student's t-test.
All CVD related deaths or events (CVD) were pooled for subsequent analyses. Time in the study was calculated from date of first screen to CVD or death from any cause or the census date (whichever occurred first). Cardiovascular event or death rates per 1000 person-years were analysed using the Kaplan-Meier method by ACR category.
The effect of ACR level at baseline on CVD was analysed using a Cox Proportional Hazards model, estimating a Hazard Ratio (HR). This analysis was conducted on the entire study sample with a total of up to seven years of follow up (n = 2445), assuming proportional hazards over time. In order to assess the potential effect of differing hazard over time, the analysis was repeated by excluding all those events or deaths that occurred in the first year subsequent to study entry and then again excluding the events or deaths that occurred in the first two years subsequent to study entry, and so on until six years from study entry. In this way these models assess the subsequent risk of a CVD event or related death for people who survived from one to six years following study entry.
Crude Hazard Ratios were calculated using Cox models. The independent contribution of albuminuria as a marker of cardiovascular disease risk was estimated using multivariate analysis. For each of the time periods, the analysis was conducted first adjusted for sex and age only (model 2, there was minimal difference in estimates stratified by gender and so to maximize precision the analysis controlled for gender rather than stratifying by gender). The second model further adjusted for a history of prior CVD and the third model also adjusted for smoking status, systolic blood pressure (adding diastolic blood pressure to the model did not appreciably alter results and so was omitted, data not shown), diabetes, body mass index and total cholesterol level, factors that have been previously found to have an association both with CVD and ACR [4, 9, 10] . All analyses were conducted using Stata statistical software v 10.0 [11] . The study was approved by the Cairns and Hinterland Health Service District Ethics Committee, with support from the relevant peak Indigenous health councils. All participants gave informed consent.
RESULTS
The study cohort had a 21.2% baseline prevalence of microalbuminuria and 6.7% of macroalbuminuria, with no difference between men and women (p = 0.3). Table  1 shows the baseline characteristics of the study population, comparing the study sample with those who participated in the baseline survey but either did not have an ACR taken (as they were deemed to be 'low risk') or had missing data. The study sample, was more likely to be female, had higher blood pressure, higher BMI, lower total cholesterol, higher prevalence of diabetes and was older, but there was no difference in the prevalence of smoking.
The rate of incident CVD events or death per 1000 person-years by ACR category and length of time since study entry is presented in Table 2 . The overall incidence of cardiovascular event or death was 92 in 13,812 person-years. The rate increased across ACR category from normal (3.3, 95% CI 2.3 -4.6) to microalbuminuria (9.8, 95% CI 6.8 -14.1) and then macroalbuminuria (35.5, 95% CI 24.8 -50.8).
Kaplan-Meier survival estimates are presented in the Figure 1 . There was decreasing survival with increases in level of albuminuria.
The overall risk of an incident cardiovascular event or death was 1.3 (95% CI 0.78 -2.31) for microalbuminuria and 4.4 (95% CI 2.52 -7.83) for macroalbuminuria compared with normal levels of albuminuria, when adjusting for age, gender, smoking, systolic blood pressure, total cholesterol and diabetes (Table 3, model 3) . The equivalent risk estimates for the sample that included those with pre-existing CVD was similar, with a HR of 1.1 (95% CI 0.70 -1.80) for microalbuminuria and 3.8 (95% CI 2.37 -6.24) for macroalbuminuria. The risk was lowest for people with macroalbuminuria in the first three years. For example, those people with macroalbuminuria that survived the first three years had a crude HR of an incident cardiovascular event or death of 13.0 (95% CI 6.45 -26.39) to a peak of 32.3 (95% CI 8.55 -121.77) for those who survived the first five years (multivariate adjustment not undertaken due to small event numbers). The hazard dropped in the 6 th year although this estimate is based on small numbers.
DISCUSSION
Macroalbuminuria increased the risk of an incident cardiovascular event or death, with increasing magnitude over time, ranging from a HR of 9.0 for those who survived the first year to HR 32.3 for those who survived the first five years. These estimates were attenuated by age, gender and the co-variates added to the model, but a strong independent association with cardiovascular disease remained. The estimates that included those with pre-existing CVD were similar in magnitude to those for incident CVD, suggesting that albuminuria may be a relevant clinical indicator in both primary health care and specialist medical settings. Microalbuminuria also consistently elevated the risk of a cardiovascular event or death compared with normal (less so than macroalbuminuria), but did not appear to follow the same time varying pattern as macroalbuminuria. These findings suggest that the risks associated with macroalbuminuria are less in the first three years than the overall hazard would suggest and so suggest that a window of opportunity exists to reduce incident cardiovascular disease and a subsequent CVD event or related death for those with pre-existing CVD before the risk increases up to three fold over the next three years.
The hazard ratio for those who survived the first six years was a third of that for the previous five year estimate. This difference may reflect small numbers of events in the seventh year and so be an unstable and non-valid estimate. However, if this is a true finding it suggests that macroalbuminuria is a strong predictor of incident cardiovascular disease in the short term (within the first six years) and less so in the long term. This finding is consistent with a study conducted in 1993 § Micro-microalbuminuria, Macro-macroalbuminuria. ¶ Each year denotes the number of events excluded-e.g. 1 year analyses all data excluding those who had a cardiovascular event or death in the previous 1 year, 2 year analyses all data excluding those who had a cardiovascular event or death in the first 2 years, etc.
where after 5 years the predictive effect of albuminuria on the risk of CVD had reduced to no effect [12] . This suggests the possibility of different trajectories of risk for different potential causal pathways between macroalbuminuria and cardiovascular disease, with one or more trajectories leading to a short term high increased risk of death and a possible other whereby macroalbuminuria is less predictive of cardiovascular disease from the start. Another possible explanation is a healthy survivor effect, where those who survive or do not develop cardiovascular disease by five years being healthier (in ways for which we were unable to adjust) and so there is an apparent reduction in the associated risk with cardiovascular disease by the seventh year. This warrants further exploration in other cohorts as it may help to understand the pathological processes involved by examining defining characteristics of the different cohorts (survivors versus those who developed cardiovascular disease).
The findings from this study may not be generalisable to other populations given the high prevalence of albuminuria and other CVD risk conditions especially diabetes in this cohort relative to the general Australian population. The magnitude of the risk estimates was also higher than has been commonly reported in the literature [2, 4] , although the reduction in risk for in the first few years relative to the overall hazard may be generalisable. There was also no difference in cardiovascular disease risk for women compared with men, a finding that has been reported from this cohort previously. This is thought to be a result of higher rates of metabolic disease especially diabetes in women compared with men and so eliminating the protective effect of being female [7] .
The findings of this study are possibly limited by under-enumeration of outcome events. This could have occurred through the data linkage process as it was undertaken manually, and it may also be that deaths were under-recorded in the latter years of the study given the time-lag involved in registering deaths and cause of death. These possible misclassification errors are likely to have been non-differential and so are likely to have had an effect of biasing the findings towards the null. For example, if an assumption is made that the sensitivity of the classification method was 95% and the specificity 99% (an ideal test), then the biasing effect on the estimate would be an increase in the relative risk from 9.7 (the equivalent of the HR of 10.8) to 19.0 [13] . The selection method for the first half of the cohort lead to fewer people being tested for ACR than the latter half of the cohort and so the results reflect that for a relatively high risk cohort. While this introduces a potential risk of selection bias, there was no evidence for this on re-analysis of the data restricted to only those communities where ACR testing was universal (16 of the 26 communities). There was minimal change in the effect estimates, although they were measured with less precision (data not presented, available on request from the authors).
In summary, the findings here suggest that the risk of CVD with macroalbuminuria are not linear over time, and that the first three years after finding macroalbuminuria provide a window of opportunity to manage the risk of both incident and pre-existing cardiovascular disease before the risk of a CVD related event or death elevates substantially in subsequent years. These findings together suggest the need for increased use of ACR testing in the course of clinical care for adults, including those who are apparently at low risk of CVD.
This might represent an opportunity to step up primary health care-based clinical intervention, especially aggressive management of albuminuria with a view to reversing or reducing subsequent CVD and other events. Further, clinicians identifying an elevated ACR should consider a broader assessment of the patient and management of potential cardiovascular risk. This change in practice could be monitored in cohorts over time utilising new capabilities in unit level record linkage.
